AMSTERDAM, June 14, 2011 /PRNewswire/ --
BMEYE B.V., the inventor of noninvasive, beat-to-beat cardiac output and blood pressure monitoring, announces the launch of DO2I - the delivery of oxygen to the tissues. DO2I is the multiple of cardiac output, oxygen saturation and hemoglobin and is a critical parameter for clinicians. This new parameter is made available noninvasively for the first time by the combination of two innovative technologies: the BMEYE Nexfin CO-TREK for noninvasive and continuous cardiac output monitoring and the Masimo Rainbow SET for noninvasive and continuous hemoglobin and oxygen saturation monitoring. In addition BMEYE launched two new parameters, Pulse Pressure Variation (PPV) and Stroke Volume Variation (SVV), which are essential for monitoring of the fluid responsiveness status of the patient. All variables provided are real-time, beat-to-beat measurements of hemodynamic parameters, which enable clinicians to detect impending hemodynamic crisis and optimize treatment before tissue hypoxia and organ injury ensues in peri-operative period and in critical care.
Hemodynamic monitoring has traditionally relied upon invasive, costly, intermittent, or unreliable methods to assist clinicians in maintaining adequate oxygen delivery, tissue perfusion and to prevent hypoxia and its irreversible damage. However, the ccNexfin with Masimo Rainbow SET offers a totally noninvasive method of providing some of the most advanced cardiovascular and hemodynamic monitoring capabilities available today. It utilizes a BMEYE finger cuff to capture and continuously measure beat-to-beat blood pressure, mean arterial pressure (MAP), cardiac output (CO), stroke volume (SV), systemic vascular resistance (SVR), dynamic fluid responsiveness parameters (PPV, SVV), index of contractility (dP/dt) and a Masimo finger sensor to noninvasively and continuously measure hemoglobin (SpHb®), oxygen saturation (SpO2), and perfusion index (PI). The combined technologies provide the unique parameter oxygen delivery (DO2I).
These integrated functional hemodynamic monitoring data allow clinicians to predict and proactively address the early signs of hemodynamic instability during the peri-operative period and in critical situations.
“With the integration of PPV and SVV we further strengthen our ccNexfin product offering, with the addition of DO2I we take hemodynamic monitoring to the next level” stated Rob de Ree, CEO of BMEYE. “We are proud to be the first company to provide this parameter to the clinic and combined with the available parameters in the ccNexfin to have the potential to provide earlier diagnosis and early goal-directed therapies in anesthesia and emergency care to improve patient care while reducing costs.”
Prof. Azriel Perel from the Tel Aviv University stated: “For me personally it is a dream come true. For the first time we have a totally noninvasive advanced hemodynamic monitor which can provide us with continuous DO2I within minutes without the complications that are associated with traditional invasive techniques. This is a great step forward in the management of patients in the operating room and the intensive care unit. I believe that by making s DO2I and fluid responsiveness parameters available noninvasively, in addition to cardiac output and blood pressure the ccNexfin has the potential to change medical practice in the peri-operative setting.”
About BMEYE
BMEYE, a Dutch company based in Amsterdam, The Netherlands, develops innovative medical devices with broad application in clinical settings that require cardiovascular monitoring. Specifically, BMEYE produces patient monitors that noninvasively measure continuous blood pressure and cardiac output. BMEYE’s mission: BMEYE is the premier provider and will set the standard of noninvasive, beat-to-beat, user-friendly cardiovascular monitoring systems, to improve patient care and reduce healthcare costs.
